All patients with stable ischemic heart disease (SIHD) should be managed with guideline-directed medical therapy (GDMT), which reduces progression of atherosclerosis and prevents coronary thrombosis. Revascularization is also indicated in patients with SIHD and progressive or refractory symptoms, despite medical management. Whether a strategy of routine revascularization (with percutaneous coronary intervention or coronary artery bypass graft surgery as appropriate) plus GDMT reduces rates of death or myocardial infarction, or improves quality of life compared to an initial approach of GDMT alone in patients with substantial ischemia is uncertain. Opinions run strongly on both sides, and evidence may be used to support either approach. Careful review of the data demonstrates the limitations of our current knowledge, resulting in a state of community equipoise. The ongoing ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) is being performed to determine the optimal approach to managing patients with SIHD, moderate-to-severe ischemia, and symptoms that can be and is an officer, director, or trustee of Evidint and Scanadu. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Manuscript received July 3, 2015; revised manuscript received September 10, 2015, accepted September 22, 2015. 
and cardiovascular death (1, 2) . In patients with biomarker-positive ACS, it is widely accepted that routine revascularization, in addition to GDMT, reduces the short-and long-term rates of death and MI compared with a more conservative approach (3) (4) (5) . By contrast, the extent to which routine revascularization reduces death or MI, or improves quality of life (QoL) in patients with stable ischemic heart disease (SIHD) represents one of the greatest uncertainties in contemporary cardiology. Given that an estimated 15.5 million Americans have CAD, and that revascularization is performed in more than
million patients per year in the United
States alone (6) , the appropriate (but judicious) application of revascularization has enormous implications for the medical and economic health of the nation and the global community.
Early randomized trials of coronary artery bypass graft (CABG) surgery versus conservative care in patents with SIHD performed several decades ago suggested a survival benefit for CABG in patients with extensive anatomic disease, in whom a large amount of myocardium was at risk (left main disease, 3-vessel disease, and possibly 2-vessel disease involving the proximal left anterior descending coronary artery) (7) . Ischemia on an exercise stress test also identified patients in whom mortality was reduced with CABG compared with medical therapy (MT) (7) . These earlier randomized trials of CABG versus MT, however, antedated the more contemporary use of "disease-modifying" pharmacological 1. Most data from large observational studies and from within randomized trials suggest a relationship between ischemia and subsequent death and MI.
2. Revascularization relieves ischemia to a greater extent than the best medical therapy.
3. Several large-scale observational studies and some randomized data have demonstrated a reduction in spontaneous MI and death with revascularization compared with medical therapy in SIHD.
4. Both PCI and CABG revascularization strategies are continually being improved, with contemporary stent technologies and surgical techniques documented to be more effective in relieving ischemia and reducing death and MI than prior approaches.
5. Nearly all studies suggest that routine revascularization more effectively reduces angina and the need for antianginal medications, and improves QoL more than GDMT for at least several years. The rates converge over time only in part because many GDMT patients have "crossed over" and required revascularization for progressive symptoms.
6. Adherence to GDMT (especially multiple daily medications) is difficult and not routinely achieved. Many patients prefer the more immediate reduction in symptoms and avoidance of antianginal medications achievable with revascularization compared with GDMT.
7. An initial strategy of routine revascularization does not preclude patients benefitting from GDMT that inhibit coronary atherosclerosis and thrombosis. However, by reducing the requirement for antianginal medications, revascularization may facilitate compliance with GDMT proven to reduce MI and death.
Favors an Initial Conservative Strategy 1. GDMT is necessary in all SIHD patients, whether or not revascularization is performed, because it prevents MI and death. Revascularization is an alternative to antianginal medication, not an alternative to GDMT. Patients who undergo PCI and CABG must still take GDMT to optimize outcomes.
2. Recent studies in the current GDMT era have not demonstrated a link between ischemia and death or MI.
3. PCI, the most common form of revascularization, has never been shown in randomized trials to improve survival in SIHD.
4. Medical therapy is continually being improved. Prolonged dual antiplatelet therapy results in reductions in the composite rate of cardiovascular death, MI, and stroke following remote MI, and stent thrombosis and MI after stents. PCSK9 inhibitors reduce LDL by $50% in patients with or without concomitant statin treatment, and may reduce death and MI.
5. The QoL benefit from revascularization appears to be time limited, more so for PCI than for CABG. There are challenges to assessing QoL in the absence of sham procedure control groups.
6. Because revascularization has not been proven to reduce death or MI in SIHD, a trial of GDMT should be tried before elective revascularization to see if symptom relief is adequate. An initial trial of GDMT without revascularization does not increase the risk of death or MI. in whom a quantitative stress SPECT study was performed (671 of whom were treated with early revascularization), the mean 1.9-year rate of cardiac mortality in nonrevascularized patients increased monotonically, from 0.7% in those with no ischemia to 6.7% in those with >20% ischemia (Figure 2 ) (26).
After accounting for baseline variables and the propensity for revascularization, a strong relationship was present between the percentage of myocardial ischemia and cardiac mortality.
In the COURAGE serial nuclear substudy, 314
patients underwent rest/stress SPECT before treatment and at 6 to 18 months (mean 374 AE 50 days), with the amount of ischemia assessed at a blinded core laboratory (27 CI ¼ confidence interval; HR ¼ hazard ratio; SIHD ¼ stable ischemic heart disease.
Ischemia Revascularization Equipoise .
Stone et al. 
P<0.0001
Mean change (95%CI) = -0.5% (-1.6%, 0.6%) P=0.93 
18.9% with ≥5% ischemia reduction
Reduction in inducible ischemia from baseline to 6 to 18 months is shown in patients treated with OMT with versus without a strategy of routine upfront PCI, as assessed by myocardial perfusion scintigraphy. Left graph: with routine upfront PCI; right graph: without. The reduction in ischemia in the PCI arm was significant, whereas there was no significant reduction in ischemia with OMT. Adapted with permission from Shaw et al. (27) . CI ¼ confidence interval; OMT ¼ optimal medical therapy; PCI ¼ percutaneous coronary intervention.
Ischemia Revascularization Equipoise -, 2015:---angina at 10 years was 64% with CABG, 59% with PCI, and 43% with OMT (p < 0.001).
In the COURAGE trial, randomization of 2,287 patients to PCI plus OMT versus OMT alone did not reduce the long-term rate of death or MI (8) . Nor, however, did PCI worsen prognosis, and crossover to PCI for progressive symptoms or ACS was required in 32% of OMT patients during a median 4.6-year followup. Moreover, patients randomized to PCI had less documented angina, were more likely to be anginafree (despite requiring fewer nitrates and calciumchannel blockers), and had improved QoL for up to Others have reported similar trends (39, 40 PCI ¼ percutaneous coronary intervention.
Stone et al. Adherence to biology-altering medications, such
Ischemia Revascularization Equipoise Participants of 2 large surveys were willing to sacrifice 4 and 6 months of life, respectively, to avoid other abbreviations as in Figure 4 .
Stone et al. Figures 1, 3, 4 , and 5.
Ischemia Revascularization Equipoise (B) Moderate-to-severe ischemia. Ischemia severity was determined by the participating sites, and was not associated with risk of death or MI. PCI did not reduce death or MI in patients with moderate or severe ischemia. Adapted with permission from Shaw et al. (48) .
Abbreviations as in Figures 3 and 4 .
p=0.001
Amount of ischemia 0% -<5% myocardium, n=241 5% -<10% myocardium, n=192 ≥10% myocardium, n=188
Burden of angiographic atherosclerosis 0-5, n=230 6-13, n=242 14-17, n=149 Number at risk: Stone et al.
Ischemia Revascularization Equipoise A B
(A) Death. (B) Nonfatal MI. This meta-analysis required 50% statin use and only included studies of SIHD that directly compared the 2 randomized groups.
The addition of PCI to MT did not reduce the incidence of death or MI as compared with MT alone. Adapted with permission from Stergiopoulos et al. (73) .
OR ¼ odds ratio; other abbreviations as in Figures 3, 4 , and 5.
Stone et al. In the COURAGE trial, the addition of PCI to OMT was not cost-effective (77) . The added cost of PCI was approximately $10,000, without significant gain in life-years or quality-adjusted life-years (QALYs).
The incremental cost-effectiveness ratio varied from just over $168,000 to just under $300,000 per lifeyear or QALY gained with PCI. In the BARI 2D study, cost-effectiveness also favored MT over prompt revascularization (78) . Lifetime projections of costeffectiveness found MT to be cost-effective ($600
per life-year added) compared with PCI, but suggested that CABG may be cost-effective ($47,000
per life-year added). In the FAME-2 trial, the incremental cost-effectiveness ratio of PCI was $36,000
per QALY (79) , and the authors concluded that PCI was economically attractive compared with the best available MT. However, this analysis was limited, because 12-month QoL data was available for only 11% of patients in the economic substudy.
In the era of patient-centered care, patients should For example, in the STICH trial, CABG reduced mortality in both the per-protocol and crossover patient populations (although whether ischemia was a modulating influence in these cohorts was not reported) (84) . It should also be acknowledged that the risk profile of patients with SIHD may vary greatly, independent of the degree of ischemia, and that optimal tools for risk stratification are lacking.
When data are conflicting or individual trials are 
